| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Shares of Candel Therapeutics Inc (NASDAQ:CADL) climbed 5.3% to $5.90 Wednesday morning, gaining investor attention on Stocktwits after the company announced it received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its lead candidate, CAN-2409.
What To Know: The therapy targets newly diagnosed, localized intermediate-to-high-risk prostate cancer. The RMAT designation, aimed at expediting therapies for serious or life-threatening conditions, follows positive Phase 3 trial results.
CAN-2409, in combination with valacyclovir and standard radiation, significantly improved disease-free survival, showing a 30% reduction in risk of recurrence or death and a 38% reduction in prostate-specific disease progression. Other markers, such as PSA response and pathological complete response, also favored the treatment arm.
This milestone adds to the therapy's prior Fast Track status and was granted based on an FDA-reviewed Special Protocol Assessment. Candel plans to file for Biologics License Application (BLA) by the end of 2026.
CEO Dr. Paul Peter Tak emphasized the urgency for innovation in early-stage prostate cancer and sees RMAT as a key step toward expediting approval. The safety profile remained consistent with past studies, with no new concerns raised.
Read Also: Joby Aviation Stock Is Flying Today: What’s Driving The Action?
By now you're likely curious about how to participate in the market for Candel Therapeutics – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.
In the case of Candel Therapeutics, which is trading at $5.90 as of publishing time, $100 would buy you 16.95 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
According to data from Benzinga Pro, CADL has a 52-week high of $14.60 and a 52-week low of $3.78.
Photo: Shutterstock
Posted In: CADL
